Taking a Take a look at Key Metrics Versus Estimates
Johnson & Johnson (JNJ) reported $23.71 billion in income for the quarter ended December 2022, representing a year-over-year decline of 4.4%. EPS of $2.35 for a similar interval compares to $2.13 a yr in the past.
The reported income represents a shock of -0.22% over the Zacks Consensus Estimate of $23.76 billion. With the consensus EPS estimate being $2.22, the EPS shock was +5.86%.
Whereas traders scrutinize income and earnings modifications year-over-year and the way they evaluate with Wall Avenue expectations to find out their subsequent transfer, some key metrics all the time supply a extra correct image of an organization’s monetary well being.
Since these metrics play an important position in driving the top- and bottom-line numbers, evaluating them with the year-ago numbers and what analysts estimated about them helps traders higher challenge a inventory’s value efficiency.
Right here is how Johnson & Johnson carried out within the simply reported quarter by way of the metrics most generally monitored and projected by Wall Avenue analysts:
-
Gross sales-Pharmaceutical-INVOKANA / INVOKAMET-WW: $91 million in comparison with the $96.66 million common estimate based mostly on 4 analysts. The reported quantity represents a change of -24.2% yr over yr.
-
Gross sales-US: $12.52 billion versus $12.63 billion estimated by 4 analysts on common. In comparison with the year-ago quarter, this quantity represents a +2.9% change.
-
Gross sales-Worldwide: $11.19 billion in comparison with the $11.12 billion common estimate based mostly on 4 analysts. The reported quantity represents a change of -11.5% yr over yr.
-
Pharmaceutical Phase -Oncology -DARZALEX- WW: $2.08 billion versus $2.07 billion estimated by 4 analysts on common. In comparison with the year-ago quarter, this quantity represents a +26.6% change.
-
Gross sales-Med Gadgets & Diagnostics (MedTech): $6.78 billion versus $6.97 billion estimated by 5 analysts on common. In comparison with the year-ago quarter, this quantity represents a -1.2% change.
-
Gross sales-Pharmaceutical: $13.16 billion in comparison with the $13.04 billion common estimate based mostly on 5 analysts. The reported quantity represents a change of -7.9% yr over yr.
-
Gross sales-Client Well being: $3.77 billion versus $3.73 billion estimated by 5 analysts on common. In comparison with the year-ago quarter, this quantity represents a +3% change.
-
Gross sales-Med Gadgets & Diagnostics-WW-SPINE & OTHER: $699 million versus $703.83 million estimated by 4 analysts on common.
-
Gross sales-Med Gadgets & Diagnostics-WW-Superior Surgical procedure: $1.11 billion versus the four-analyst common estimate of $1.19 billion.
-
Gross sales-Med Gadgets & Diagnostics-Complete Surgical procedure: $2.38 billion versus the four-analyst common estimate of $2.50 billion.
-
Gross sales-Med Gadgets & Diagnostics-WW-TRAUMA: $710 million versus $734.36 million estimated by 4 analysts on common.
View all Key Firm Metrics for Johnson & Johnson right here>>>
Shares of Johnson & Johnson have returned -5.2% over the previous month versus the Zacks S&P 500 composite’s +4.6% change. The inventory at the moment has a Zacks Rank #3 (Maintain), indicating that it might carry out consistent with the broader market within the close to time period.
Need the most recent suggestions from Zacks Funding Analysis? At present, you’ll be able to obtain 7 Greatest Shares for the Subsequent 30 Days. Click to get this free report
Johnson & Johnson (JNJ) : Free Stock Analysis Report